Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

UKDRI

- PMLiVE

Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved

The real-world findings support the long-term benefits of continuous treatment

- PMLiVE

AL-S Pharma release new data from AP-101 phase 2 trial for ALS

ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord

- PMLiVE

Grifols share results identifying early signs of Parkinson’s disease

Parkinson’s disease affects over six million people globally

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

TRIMTECH Therapeutics establishes Scientific Advisory Board

Alessio Ciulli has been appointed as Chair of the board

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla shows growing benefit in long-term study

More than seven million people in the US are affected by the neurodegenerative disease

- PMLiVE

Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

- PMLiVE

Roche shares promising data from Alzheimer’s disease development portfolio

The company is planning to initiate phase 3 studies of trontinemab in early AD this year

- PMLiVE

Ventyx’s investigational NLRP3 inhibitor shows promise in Parkinson’s disease

Planning is currently underway for a placebo-controlled trial of the candidate

- PMLiVE

Roche to advance Parkinson’s disease candidate into phase 3 development

More than ten million people worldwide are living with the neurodegenerative disorder

- PMLiVE

UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

It is hoped that the test could be available for widespread UK use in the coming years

- PMLiVE

Sanofi gains access to Alzheimer’s candidate through $470m Vigil acquisition

A phase 2 trial of the drug is expected to launch in the third quarter of this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links